What is QbDVision?
QbDVision operates as a sophisticated, cloud-native platform engineered to unify knowledge across product and manufacturing processes. By automating essential development workflows, the company provides a robust alternative to legacy product lifecycle management (PLM) systems. Its core offering, the Digital CMC platform, is specifically tailored for the biopharmaceutical sector, enabling teams to manage complex tech transfers and operational workflows with real-time, data-driven insights. This focus on quality and compliance ensures that life-changing therapies reach the market faster, effectively reducing cycle times while maintaining the highest standards of operational excellence.
How much funding has QbDVision raised?
QbDVision has raised a total of $30.3M across 2 funding rounds:
Angel/Seed
$2.3M
Series A
$28M
Angel/Seed (2019): $2.3M, investors not publicly disclosed
Series A (2025): $28M led by Northpond Ventures, Hudson Park Capital, S3 Ventures, Create Health Ventures, and Wanxiang Healthcare Investments (WHI)
Key Investors in QbDVision
S3 Ventures
S3 Ventures is the largest venture capital firm focused on Texas, partnering with startups across major cities to provide patient, flexible capital for high-impact companies in healthcare technology and business software.
Create Health Ventures
Create Health Ventures specializes in early-stage digital health businesses, leveraging deep operational expertise to support B2B software companies aimed at improving patient outcomes and healthcare access.
Wanxiang Healthcare Investments (WHI)
Wanxiang Healthcare Investments is a corporate-backed group focusing on digital health and healthcare technologies, providing long-term strategic support for companies from Series A through growth stages.
What's next for QbDVision?
With this recent capital injection, QbDVision is poised to expand its footprint in the global biopharma market. The strategic roadmap likely includes the enhancement of its data analytics capabilities and the scaling of its customer success teams to support a growing roster of enterprise clients. As the industry continues to prioritize digital transformation, QbDVision's ability to provide a single source of truth for CMC data will be a critical differentiator. The company is expected to leverage these funds to further refine its automated workflows, ultimately setting a new standard for efficiency in the development of complex therapeutic products.
See full QbDVision company page
